Progress of CD47 in treatment of lymphoma
10.3760/cma.j.cn115356-20200907-00216
- VernacularTitle:CD47在淋巴瘤治疗中的研究进展
- Author:
Yuhan MA
;
Wei SANG
;
Kailin XU
- From:
Journal of Leukemia & Lymphoma
2021;30(5):314-317
- CountryChina
- Language:Chinese
-
Abstract:
As a transmembrane protein, CD47 is widely distributed in a variety of cells. It can bind to signal regulatory protein alpha (SIRPα) on macrophages and release inhibitory signals, thus avoiding phagocytosis of macrophages. In lymphoma cells, the expression of up-regulation of CD47 expression in lymphoma cells is one of the important mechanisms for inducing immune escape, and it is also a potential therapeutic target. This article reviews the research progress of CD47-induced immune escape, monoclonal antibodies targeting CD47 and cellular immunotherapy in the treatment of lymphoma.
